Clinical Trial: Efficacy and Safety of Faropenem in Bangladeshi Adult Patients with Community-Acquired Bacterial Pneumonia (CABP)

U.S., Feb. 1 -- ClinicalTrials.gov registry received information related to the study (NCT06804096) titled 'Efficacy and Safety of Faropenem in Bangladeshi Adult Patients with Community-Acquired Bacterial Pneumonia (CABP)' on Jan. 26.

Brief Summary: The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav at 625 mg, also three times daily, along wi...